DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting

Montrouge, France, May well 12, 2022

DBV Technologies Announces Final results of Its 2022 Common and Amazing Basic Conference

Shareholders Approved All Proposed Realternatives

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Inventory Sector: DBVT), a scientific-phase biopharmaceutical organization, currently held its Everyday and Extraordinary Common Assembly. The Common Assembly was chaired by Michel de Rosen, Chairman of DBV Technologies.

The Company’s shareholders authorised all resolutions submitted by the Board of Directors. These resolutions and their results are posted on the Traders & Media portion of the Company’s website: https://www.dbv-technologies.com/investor-relations/money-information/yearly-studies/.

About DBV Technologies
DBV Technologies is producing Viaskin™, an investigational proprietary technological know-how platform with wide possible programs in immunotherapy. Viaskin is primarily based on epicutaneous immunotherapy, or EPIT™, DBV Technologies’ process of offering biologically energetic compounds to the immune program as a result of intact skin. With this new class of non-invasive item candidates, the Business is devoted to safely and securely reworking the treatment of food stuff allergic people. DBV Technologies’ food allergies courses contain ongoing clinical trials of Viaskin Peanut. DBV Technologies has world headquarters in Montrouge, France, and North American functions in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each and every symbolizing one-50 % of a single standard share) are traded on the Nasdaq World-wide Decide on Industry (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Systems
+1 857-529-2363
[email protected]

Media Get in touch with
Angela Marcucci
DBV Technologies
+1 646-842-2393

[email protected]

Attachment